Last 12 months
Inside the activity.
0 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2020 Filed Jul 23, 2020 23:32 UTC |
LEUNG GABRIELDirector
|
SaleOrdinary Shares | 500 | $65.07 | $32,536.50 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · price: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 500 shares in multiple trades at prices ranging from $65.00 to $65.22. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 23:32 UTC |
LEUNG GABRIELDirector
|
Exercise / conversionOrdinary Shares | 500 | $7.03 | $3,515.00 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 16:20 UTC |
Weinberg UriChief Science Officer
|
GrantOrdinary Shares | 325 | $50.41 | $16,381.63 |
DisclosureSEC source: 0001645113-20-000093 · wf-form4_159423964284425.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,357 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 16:24 UTC |
Longsworth Todd ChristopherGeneral Counsel
|
GrantOrdinary Shares | 325 | $50.41 | $16,381.63 |
DisclosureSEC source: 0001645113-20-000095 · wf-form4_159423984492801.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,078 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:25 UTC |
Shah PriteshChief Commercial Officer
|
GrantOrdinary Shares | 325 | $50.41 | $16,381.63 |
DisclosureSEC source: 0001645113-20-000096 · wf-form4_159423991775624.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,018 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:22 UTC |
GROENHUYSEN WILHELMUS CMChief Financial Officer
|
GrantOrdinary Shares | 253 | $50.41 | $12,752.47 |
DisclosureSEC source: 0001645113-20-000094 · wf-form4_159423975754641.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,639 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
GrantOrdinary Shares | 284 | $50.41 | $14,315.02 |
DisclosureSEC source: 0001645113-20-000092 · wf-form4_159423951502640.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,632 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. Read SEC document |
| July 07, 2020 Filed Aug 3, 2020 21:53 UTC |
Benaim ElyChief Medical Officer
|
GrantOrdinary Shares | 325 | $50.41 | $16,381.63 |
DisclosureSEC source: 0001645113-20-000114 · wf-form4_159649157316820.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,357 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. F3 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:14 UTC |
LEUNG GABRIELDirector
|
GrantOptions to Buy Ordinary Shares · Derivative | 5,101 | $0.00 Strike: $67.89 | $0.00 |
DisclosureSEC source: 0001645113-20-000091 · wf-form4_159200002154383.xml · derivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:14 UTC |
LEUNG GABRIELDirector
|
GrantRestricted Stock Units | 2,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000091 · wf-form4_159200002154383.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:12 UTC |
HILLEMAN JERYL LDirector
|
GrantOptions to Buy Ordinary Shares · Derivative | 5,101 | $0.00 Strike: $67.89 | $0.00 |
DisclosureSEC source: 0001645113-20-000090 · wf-form4_159199992057717.xml · derivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:12 UTC |
HILLEMAN JERYL LDirector
|
GrantRestricted Stock Units | 2,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000090 · wf-form4_159199992057717.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,900 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:11 UTC |
VERNON W ANTHONYDirector
|
GrantOptions to Buy Ordinary Shares · Derivative | 5,101 | $0.00 Strike: $67.89 | $0.00 |
DisclosureSEC source: 0001645113-20-000089 · wf-form4_159199985639264.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:11 UTC |
VERNON W ANTHONYDirector
|
GrantRestricted Stock Units | 2,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000089 · wf-form4_159199985639264.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,130 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:09 UTC |
Madden Martin J.Director
|
GrantOptions to Buy Ordinary Shares · Derivative | 5,101 | $0.00 Strike: $67.89 | $0.00 |
DisclosureSEC source: 0001645113-20-000088 · wf-form4_159199976247040.xml · derivative · entry 2 Madden Martin J. · CIK 0001696864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:09 UTC |
Madden Martin J.Director
|
GrantRestricted Stock Units | 2,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000088 · wf-form4_159199976247040.xml · nonDerivative · entry 1 Madden Martin J. · CIK 0001696864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,806 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:07 UTC |
Hung DavidDirector
|
GrantOptions to Buy Ordinary Shares · Derivative | 5,101 | $0.00 Strike: $67.89 | $0.00 |
DisclosureSEC source: 0001645113-20-000087 · wf-form4_159199964610645.xml · derivative · entry 2 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:07 UTC |
Hung DavidDirector
|
GrantRestricted Stock Units | 2,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000087 · wf-form4_159199964610645.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,900 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:03 UTC |
McCoy Sherilyn SDirector
|
GrantOptions to Buy Ordinary Shares · Derivative | 5,101 | $0.00 Strike: $67.89 | $0.00 |
DisclosureSEC source: 0001645113-20-000086 · wf-form4_159199941976503.xml · derivative · entry 2 McCoy Sherilyn S · CIK 0001422968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:03 UTC |
McCoy Sherilyn SDirector
|
GrantRestricted Stock Units | 2,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000086 · wf-form4_159199941976503.xml · nonDerivative · entry 1 McCoy Sherilyn S · CIK 0001422968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,900 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:14 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 2,595 | $64.78 | $168,104.10 |
DisclosureSEC source: 0001645113-20-000083 · wf-form4_158948727942417.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,616 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| May 11, 2020 Filed May 12, 2020 20:22 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 1,611 | $63.73 | $102,665.81 |
DisclosureSEC source: 0001645113-20-000079 · wf-form4_158931495360958.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,211 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 11, 2020 Filed May 12, 2020 20:13 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
SaleOrdinary Shares | 31,332 | $63.73 | $1,996,725.70 |
DisclosureSEC source: 0001645113-20-000076 · wf-form4_158931439083079.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,958 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units vested on May 8, 2020. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 08, 2020 Filed May 11, 2020 16:22 UTC |
Weinberg UriChief Science Officer
|
Exercise / conversionRestricted Share Units · Derivative | 1,402 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000075 · wf-form4_158922851155255.xml · derivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,803 Underlying: Ordinary Shares · 1,402 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 08, 2020 Filed May 11, 2020 16:22 UTC |
Weinberg UriChief Science Officer
|
Exercise / conversionOrdinary Shares | 1,402 | $63.84 | $89,503.68 |
DisclosureSEC source: 0001645113-20-000075 · wf-form4_158922851155255.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:17 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionRestricted Stock Units · Derivative | 58,767 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · derivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 58,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:17 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
SaleOrdinary Shares | 31,903 | $63.50 | $2,025,872.40 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · nonDerivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681,290 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:17 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionOrdinary Shares | 58,767 | $63.84 | $3,751,685.28 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:22 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionRestricted Share Units · Derivative | 4,206 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000079 · wf-form4_158931495360958.xml · derivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,410 Underlying: Ordinary Shares · 4,206 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:22 UTC |
Benaim ElyChief Medical Officer
|
Exercise / conversionOrdinary Shares | 4,206 | $63.84 | $268,511.04 |
DisclosureSEC source: 0001645113-20-000079 · wf-form4_158931495360958.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:17 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionRestricted Share Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · derivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,767 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:17 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
SaleOrdinary Shares | 30,993 | $64.74 | $2,006,517.81 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,426 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:17 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionOrdinary Shares | 58,768 | $64.77 | $3,806,403.36 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:41 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · derivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,535 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:41 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionOrdinary Shares | 58,768 | $64.15 | $3,769,967.20 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · nonDerivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:41 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
SaleOrdinary Shares | 29,881 | $64.27 | $1,920,451.87 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,883 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:48 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 1,149 | $62.20 | $71,467.80 |
DisclosureSEC source: 0001645113-20-000072 · wf-form4_158888450373702.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,693 F1 · security: On March 10, 2020, the reporting person filed a Form 4 that included information labeled "Restricted Share Units" in column 1, table 1. All shares reported in that table should have been with respect to "Ordinary Shares" and all information in such Form 4 and all subsequent Form 4 reports refer to Ordinary Shares only. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:41 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · derivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,303 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:41 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
SaleOrdinary Shares | 30,283 | $62.47 | $1,891,718.44 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,764 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:41 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionOrdinary Shares | 58,768 | $61.40 | $3,608,355.20 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:32 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 1,184 | $60.08 | $71,133.54 |
DisclosureSEC source: 0001645113-20-000069 · wf-form4_158871072233446.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,842 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:52 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000070 · wf-form4_158880193641944.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,071 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:52 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
Exercise / conversionOrdinary Shares | 58,768 | $60.48 | $3,554,288.64 |
DisclosureSEC source: 0001645113-20-000070 · wf-form4_158880193641944.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:32 UTC |
Shah PriteshChief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 2,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000069 · wf-form4_158871072233446.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,333 Underlying: Ordinary Shares · 2,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:32 UTC |
Shah PriteshChief Commercial Officer
|
Exercise / conversionOrdinary Shares | 2,333 | $65.80 | $153,511.40 |
DisclosureSEC source: 0001645113-20-000069 · wf-form4_158871072233446.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:03 UTC |
Ambrogi Michael J.Chief Operating Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 35,745 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · derivative · entry 8 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,514 Underlying: Ordinary Shares · 35,745 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:03 UTC |
Ambrogi Michael J.Chief Operating Officer
|
SaleOrdinary Shares | 377 | $71.75 | $27,050.88 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · nonDerivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,867 F4 · price: On April 14, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 377 shares in multiple trades at prices ranging from $71.64 to $71.88. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:03 UTC |
Ambrogi Michael J.Chief Operating Officer
|
SaleOrdinary Shares | 27,142 | $70.99 | $1,926,919.15 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · nonDerivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,244 F3 · price: On April 14, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 27,142 shares in multiple trades at prices ranging from $70.62 to $71.51. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:03 UTC |
Ambrogi Michael J.Chief Operating Officer
|
Exercise / conversionOrdinary Shares | 35,745 | $7.15 | $255,576.75 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:03 UTC |
Ambrogi Michael J.Chief Operating Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 22,755 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · derivative · entry 7 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,259 Underlying: Ordinary Shares · 22,755 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.